Research graph
References from Early Onset of AbobotulinumtoxinA Effects in Post-Stroke Upper Limb Spasticity: A Prospective Observational Pilot Study. Local targets link to admitted publications; unresolved targets remain external evidence.
European consensus table on the use of botulinum toxin type A in adult spasticity
10.2340/16501977-0303 · 2009 · External reference
Spasticity after stroke: Its occurrence and association with motor impairments and activity limitations
10.1161/01.str.0000105386.05173.5e · 2004 · External reference
Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the therapeutics and technology assessment subcommittee of the American academy of neurology
10.1212/01.wnl.0000311389.26145.95 · 2008 · External reference
Efficacy and safety of botulinum toxin type A for limb spasticity after stroke: A meta-analysis of randomized controlled trials
10.1155/2019/8329306 · 2019 · External reference
Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke
10.1056/nejmoa011892 · 2002 · External reference
Botulinum neurotoxins: Genetic, structural and mechanistic insights
10.1038/nrmicro3295 · 2014 · External reference
Botulinum neurotoxins: Biology, pharmacology, and toxicology
10.1124/pr.116.012658 · 2017 · External reference
Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity
2013 · External reference
Botulinum neurotoxin type A is internalized and translocated from small synaptic vesicles at the neuromuscular junction
10.1007/s12035-013-8423-9 · 2013 · External reference
Physiological effects of botulinum toxin in spasticity
10.1002/mds.20065 · 2004 · External reference
Clinical applications of botulinum toxin
10.1016/j.mib.2012.05.012 · 2012 · External reference
Incobotulinumtoxina (Xeomin®) versus onabotulinumtoxina (Botox®): Evaluation of clinical onset of action with rating scales and electroneurography
2015 · External reference
New approach in the assessment of the tone, elasticity and the muscular resistance: Nominal scales vs MYOTON
10.1177/03946320090220s304 · 2009 · External reference
Explanation of timing of botulinum neurotoxin effects, onset and duration and clinical ways of influencing them
10.1016/j.toxicon.2015.07.013 · 2015 · External reference
Test-retest reliability and inter-rater reliability of the Modified Tardieu Scale and the Modified Ashworth Scale in hemiplegic patients with stroke
2014 · External reference
Mouse compound muscle action potential assay: An alternative method to conduct the LD50 botulinum toxin type A potency test
10.1016/j.toxicon.2012.05.003 · 2012 · External reference
Quantitative determination of biological activity of botulinum toxins utilizing compound muscle action potentials (CMAP), and comparison of neuromuscular transmission blockage and muscle flaccidity among toxins
10.1016/j.toxicon.2009.09.005 · 2010 · External reference
Changes in passive mechanical properties of the gastrocnemius muscle at the muscle fascicle and joint levels in stroke survivors
10.1016/j.apmr.2008.11.004 · 2009 · External reference
Botulinum neurotoxins: Mechanism of action
10.1007/164_2020_355 · 2021 · External reference
A review of the properties and limitations of the Ashworth and Modified Ashworth Scales
10.1191/026921599677595404 · 1999 · External reference
Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans
10.1016/s0304-3940(98)00775-7 · 1998 · External reference
How botulinum toxin type A-occupational therapy-functional electrical stimulation modify spasticity and functional recovery in patients with upper limb spasticity post stroke
10.2174/2212707003666160728143344 · 2016 · External reference
Spasticity treatment with botulinum toxins
10.1007/s00702-007-0833-2 · 2008 · External reference
Different types of botulinum toxin in humans
10.1002/mds.20010 · 2004 · External reference
Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity
10.2147/ndt.s86978 · 2016 · External reference
10.3390/toxins17030107
10.3390/toxins17030107 · External reference
10.3390/toxins17060276
10.3390/toxins17060276 · External reference
Different types of botulinum toxin in humans
10.1002/mds.20010 · ExternalCitation · doi-reference
Physiological effects of botulinum toxin in spasticity
10.1002/mds.20065 · ExternalCitation · doi-reference
Botulinum neurotoxins: Mechanism of action
10.1007/164_2020_355 · ExternalCitation · doi-reference
Spasticity treatment with botulinum toxins
10.1007/s00702-007-0833-2 · ExternalCitation · doi-reference
Botulinum neurotoxin type A is internalized and translocated from small synaptic vesicles at the neuromuscular junction
10.1007/s12035-013-8423-9 · ExternalCitation · doi-reference
Changes in passive mechanical properties of the gastrocnemius muscle at the muscle fascicle and joint levels in stroke survivors
10.1016/j.apmr.2008.11.004 · ExternalCitation · doi-reference
Clinical applications of botulinum toxin
10.1016/j.mib.2012.05.012 · ExternalCitation · doi-reference
Quantitative determination of biological activity of botulinum toxins utilizing compound muscle action potentials (CMAP), and comparison of neuromuscular transmission blockage and muscle flaccidity among toxins
10.1016/j.toxicon.2009.09.005 · ExternalCitation · doi-reference
Mouse compound muscle action potential assay: An alternative method to conduct the LD50 botulinum toxin type A potency test
10.1016/j.toxicon.2012.05.003 · ExternalCitation · doi-reference
Explanation of timing of botulinum neurotoxin effects, onset and duration and clinical ways of influencing them
10.1016/j.toxicon.2015.07.013 · ExternalCitation · doi-reference
Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans
10.1016/s0304-3940(98)00775-7 · ExternalCitation · doi-reference
Botulinum neurotoxins: Genetic, structural and mechanistic insights
10.1038/nrmicro3295 · ExternalCitation · doi-reference
Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke
10.1056/nejmoa011892 · ExternalCitation · doi-reference
Botulinum neurotoxins: Biology, pharmacology, and toxicology
10.1124/pr.116.012658 · ExternalCitation · doi-reference
Efficacy and safety of botulinum toxin type A for limb spasticity after stroke: A meta-analysis of randomized controlled trials
10.1155/2019/8329306 · ExternalCitation · doi-reference
Spasticity after stroke: Its occurrence and association with motor impairments and activity limitations
10.1161/01.str.0000105386.05173.5e · ExternalCitation · doi-reference
New approach in the assessment of the tone, elasticity and the muscular resistance: Nominal scales vs MYOTON
10.1177/03946320090220s304 · ExternalCitation · doi-reference
A review of the properties and limitations of the Ashworth and Modified Ashworth Scales
10.1191/026921599677595404 · ExternalCitation · doi-reference
Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the therapeutics and technology assessment subcommittee of the American academy of neurology
10.1212/01.wnl.0000311389.26145.95 · ExternalCitation · doi-reference
Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity
10.2147/ndt.s86978 · ExternalCitation · doi-reference
How botulinum toxin type A-occupational therapy-functional electrical stimulation modify spasticity and functional recovery in patients with upper limb spasticity post stroke
10.2174/2212707003666160728143344 · ExternalCitation · doi-reference
European consensus table on the use of botulinum toxin type A in adult spasticity
10.2340/16501977-0303 · ExternalCitation · doi-reference
10.3390/toxins17030107
10.3390/toxins17030107 · ExternalCitation · doi-reference
10.3390/toxins17060276
10.3390/toxins17060276 · ExternalCitation · doi-reference
